Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
Autor: | Kerstin Mueller, Antoine Italiano, Zaeem Khan, Seth M. Pollack, Richard F. Riedel, Juliette C Thompson, Robin L. Jones, Brian A. Van Tine, Chet Bohac |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Population Review synovial sarcoma chemotherapy survival lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine systemic anti-cancer therapy systematic review Internal medicine Medicine education Prospective cohort study education.field_of_study business.industry Soft tissue sarcoma Retrospective cohort study medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Synovial sarcoma Clinical trial 030104 developmental biology Systematic review 030220 oncology & carcinogenesis Localized disease business |
Zdroj: | Cancers, Vol 10, Iss 11, p 417 (2018) Cancers |
ISSN: | 2072-6694 |
Popis: | Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10% of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities with specific characteristics, including differential chemo-sensitivity. The objective of this study was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer therapy specific to SS. A systematic literature review was conducted, using a custom search strategy to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only three prospective studies were identified. Survival reports varied widely between studies based on the population, in particular on the disease stage, and reporting was heterogeneous in terms of the time points reported on. For patients with localized disease, reports of five-year PFS ranged from 26% to 80.7% and five-year OS from 40% to 90.7%, whereas five-year OS for patients with metastatic disease was very low at around 10%; and in one case, 0% was reported. Only four of the included publications reported outcomes by type of systemic anti-cancer therapy received. Our study draws attention to the fact that additional prospective studies to better define the most appropriate treatment for SS in all stages and lines of therapy are still needed. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |